title: Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
authors.forename: R A
authors.initials: RA
authors.lastname: Mesa
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: C-Yang
authors.initials: CY
authors.lastname: Li
authors.forename: D P
authors.initials: DP
authors.lastname: Steensma
mesh_terms: D000208:Acute Disease; D000369:Aged, 80 and over; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D000077269:Lenalidomide; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D017354:Point Mutation; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D013792:Thalidomide; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide